title: Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
authors.affiliation: Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK, m.c.sheppard@bham.ac.uk.
authors.forename: Michael
authors.initials: M
authors.lastname: Sheppard
authors.forename: Marcello D
authors.initials: MD
authors.lastname: Bronstein
authors.forename: Pamela
authors.initials: P
authors.lastname: Freda
authors.forename: Omar
authors.initials: O
authors.lastname: Serri
authors.forename: Laura
authors.initials: L
authors.lastname: De Marinis
authors.forename: Luciana
authors.initials: L
authors.lastname: Naves
authors.forename: Liudmila
authors.initials: L
authors.lastname: Rozhinskaya
authors.forename: Karina
authors.initials: K
authors.lastname: Hermosillo Reséndiz
authors.forename: Matthieu
authors.initials: M
authors.lastname: Ruffin
authors.forename: YinMiao
authors.initials: Y
authors.lastname: Chen
authors.forename: Annamaria
authors.initials: A
authors.lastname: Colao